Back to News
Market Impact: 0.12
MEDVi QUAD New Formula 2026: Apomorphine Replaces PT-141 in Updated 4-in-1 Compounded ED Treatment
Source: Newswire
Healthcare & BiotechProduct Launches
MEDVi announced QUAD®, a compounded single-dose formulation combining sildenafil, tadalafil, apomorphine, and L-citrulline. The product change may be relevant for prospective patients before they begin a licensed-provider evaluation, but the announcement provides no financial metrics, clinical data, regulatory milestones, or expected commercial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- Snap tries to bring AR glasses to enterprise market, partnering with Nvidia, AWS and Salesforce
- Snap Shares More Details About $2,195 Specs AR Glasses, Plus Verizon Partnership
- Why is Snap stock climbing after-hours today?
- Snap launches $2,195 Specs augmented-reality glasses as AI push expands
- Snap tries to make the case again for its $2,200 smart glasses
- Premarket movers: Intel jumps on SK Hynix memory-chip talks, J.B. Hunt slides
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Analyze SEC Filings With AI: A Verification-First Guide
- AI for IR Street Intelligence: Notes, Estimates, and Peers